Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-19-004277
Filing Date
2019-06-24
Accepted
2019-06-24 16:36:45
Documents
1

Document Format Files

Seq Description Document Type Size
1 d8241945_13-g.htm SC 13G 116819
  Complete submission text file 0000919574-19-004277.txt   118416
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Subject) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-43603 | Film No.: 19915802
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G